Identification

Name
Chlorphenesin
Accession Number
DB00856  (APRD00867)
Type
Small Molecule
Groups
Approved, Vet approved, Withdrawn
Description

A centrally acting muscle relaxant. Its mode of action is unknown. Chlorphenesin is not available in the United States.

Structure
Thumb
Synonyms
  • 3-(4-Chlorophenoxy)-1,2-propanediol
  • 3-(P-Chlorophenoxy)-1,2-propanediol
  • 3-(P-Chlorophenoxy)propane-1,2-diol
  • Chlorphenesin
  • Chlorphénésine
  • Chlorphenesinum
  • Clorfenesina
  • Glycerol alpha-P-chlorophenyl ether
  • P-Chlorophenyl-alpha-glyceryl ether
Product Ingredients
IngredientUNIICASInChI Key
Chlorphenesin carbamate57U5YI11WP886-74-8SKPLBLUECSEIFO-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mycil CreamCream10 mgTopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1948-12-311996-09-10Canada
Mycil PowderPowder10 mgTopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1951-12-311996-09-10Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mycil Cream 1%Cream1.0 %TopicalWell Spring Pharmaceutical Corporation1996-04-302004-07-19Canada
Mycil Powder 1%Powder1 %TopicalRoberts Pharmaceutical1996-07-301999-08-11Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AnivyChlorphenesin (10 mg) + Benzocaine (10 mg) + Titanium dioxide (210 mg) + Zinc oxide (235 mg)OintmentTopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1988-03-231996-09-10Canada
International/Other Brands
Kolpicortin / Maolate (UpJohn ) / Rinlaxer
Categories
UNII
I670DAL4SZ
CAS number
104-29-0
Weight
Average: 202.635
Monoisotopic: 202.039671925
Chemical Formula
C9H11ClO3
InChI Key
MXOAEAUPQDYUQM-UHFFFAOYSA-N
InChI
InChI=1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2
IUPAC Name
3-(4-chlorophenoxy)propane-1,2-diol
SMILES
OCC(O)COC1=CC=C(Cl)C=C1

Pharmacology

Indication

Used, along with rest and physical therapy, to treat injuries and other painful muscular conditions. Investigated for use in trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain. Was investigated as a modulator of histamine release.

Pharmacodynamics

Chlorphenesin is a muscle relaxant. It blocks nerve impulses (or pain sensations) that are sent to the brain.

Mechanism of action

The mechanism of action of chlorphenesin is not well defined, and its effects are measured mainly by subjective responses. It is known that chlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle.

Absorption

Rapid and complete.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. 85% of a dose excreted within 24 hours as the glucuronide metabolite.

Route of elimination
Not Available
Half life

2.3-5 hours

Clearance
Not Available
Toxicity

Symptoms of a chlorphenesin overdose include drowsiness and nausea.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Chlorphenesin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Chlorphenesin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Chlorphenesin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Chlorphenesin.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Chlorphenesin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Chlorphenesin.Approved, Experimental, Investigational
AcenocoumarolChlorphenesin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Chlorphenesin.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Chlorphenesin.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Chlorphenesin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Chlorphenesin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Chlorphenesin.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Chlorphenesin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Chlorphenesin.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Chlorphenesin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Chlorphenesin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Chlorphenesin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Chlorphenesin.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Chlorphenesin.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Chlorphenesin.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Chlorphenesin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Chlorphenesin.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Chlorphenesin.Approved, Investigational
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Chlorphenesin.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Chlorphenesin.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Chlorphenesin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorphenesin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Chlorphenesin.Approved, Investigational
BazedoxifeneChlorphenesin may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Chlorphenesin.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Chlorphenesin.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Chlorphenesin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Chlorphenesin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Chlorphenesin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Chlorphenesin.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Chlorphenesin.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Chlorphenesin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Chlorphenesin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Chlorphenesin.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Chlorphenesin.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Chlorphenesin.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Chlorphenesin.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Chlorphenesin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Chlorphenesin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Chlorphenesin.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorphenesin may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Chlorphenesin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Chlorphenesin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Chlorphenesin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Chlorphenesin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Chlorphenesin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Chlorphenesin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Chlorphenesin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Chlorphenesin.Approved
ClorindioneChlorphenesin may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensChlorphenesin may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Chlorphenesin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Chlorphenesin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Chlorphenesin.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Chlorphenesin.Approved, Investigational
DaidzeinChlorphenesin may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Chlorphenesin.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Chlorphenesin.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Chlorphenesin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Chlorphenesin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Chlorphenesin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Chlorphenesin.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Chlorphenesin.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Chlorphenesin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Chlorphenesin.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Chlorphenesin.Approved, Vet Approved
DicoumarolChlorphenesin may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolChlorphenesin may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolChlorphenesin may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Chlorphenesin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Chlorphenesin.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Chlorphenesin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Chlorphenesin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Chlorphenesin.Approved
DiphenadioneChlorphenesin may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Chlorphenesin.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Chlorphenesin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Chlorphenesin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Chlorphenesin.Investigational
EpimestrolChlorphenesin may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Chlorphenesin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Chlorphenesin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Chlorphenesin.Approved
EquolChlorphenesin may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Chlorphenesin.Approved, Investigational
EstradiolChlorphenesin may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateChlorphenesin may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateChlorphenesin may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateChlorphenesin may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolChlorphenesin may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedChlorphenesin may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneChlorphenesin may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Chlorphenesin.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Chlorphenesin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Chlorphenesin.Experimental
Ethinyl EstradiolChlorphenesin may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateChlorphenesin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Chlorphenesin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Chlorphenesin.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Chlorphenesin.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Chlorphenesin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Chlorphenesin.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Chlorphenesin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Chlorphenesin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Chlorphenesin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Chlorphenesin.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Chlorphenesin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Chlorphenesin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Chlorphenesin.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Chlorphenesin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Chlorphenesin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Chlorphenesin.Approved, Investigational
FluindioneChlorphenesin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Chlorphenesin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Chlorphenesin.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Chlorphenesin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Chlorphenesin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Chlorphenesin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Chlorphenesin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Chlorphenesin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Chlorphenesin.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Chlorphenesin.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Chlorphenesin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Chlorphenesin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Chlorphenesin.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Chlorphenesin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Chlorphenesin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Chlorphenesin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chlorphenesin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Chlorphenesin.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Chlorphenesin.Approved, Investigational, Withdrawn
GenisteinChlorphenesin may increase the thrombogenic activities of Genistein.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Chlorphenesin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Chlorphenesin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Chlorphenesin.Investigational
HexestrolChlorphenesin may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Chlorphenesin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Chlorphenesin.Approved, Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Chlorphenesin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Chlorphenesin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Chlorphenesin.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Chlorphenesin.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Chlorphenesin.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Chlorphenesin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Chlorphenesin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Chlorphenesin.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Chlorphenesin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Chlorphenesin.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Chlorphenesin.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Chlorphenesin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Chlorphenesin.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Chlorphenesin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Chlorphenesin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Chlorphenesin.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Chlorphenesin.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Chlorphenesin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Chlorphenesin.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Chlorphenesin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Chlorphenesin.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Chlorphenesin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Chlorphenesin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Chlorphenesin.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Chlorphenesin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Chlorphenesin.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Chlorphenesin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Chlorphenesin.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Chlorphenesin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Chlorphenesin.Approved
MestranolChlorphenesin may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Chlorphenesin.Approved, Investigational, Withdrawn
MethallenestrilChlorphenesin may increase the thrombogenic activities of Methallenestril.Experimental
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Chlorphenesin.Approved, Vet Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Chlorphenesin.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Chlorphenesin.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Chlorphenesin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Chlorphenesin.Approved, Vet Approved
MoxestrolChlorphenesin may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Chlorphenesin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Chlorphenesin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Chlorphenesin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Chlorphenesin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Chlorphenesin.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Chlorphenesin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Chlorphenesin.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Chlorphenesin.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Chlorphenesin.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Chlorphenesin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Chlorphenesin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Chlorphenesin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Chlorphenesin.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Chlorphenesin.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorphenesin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Chlorphenesin.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Chlorphenesin.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Chlorphenesin.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Chlorphenesin.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Chlorphenesin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Chlorphenesin.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Chlorphenesin.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Chlorphenesin.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Chlorphenesin.Approved, Investigational
PhenindioneChlorphenesin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonChlorphenesin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Chlorphenesin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorphenesin.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Chlorphenesin.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chlorphenesin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Chlorphenesin.Experimental
Polyestradiol phosphateChlorphenesin may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Chlorphenesin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Chlorphenesin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Chlorphenesin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Chlorphenesin.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Chlorphenesin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Chlorphenesin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Chlorphenesin.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Chlorphenesin.Experimental
PromestrieneChlorphenesin may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Chlorphenesin.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Chlorphenesin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Chlorphenesin.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Chlorphenesin.Investigational
QuinestrolChlorphenesin may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Chlorphenesin.Approved, Experimental, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Chlorphenesin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Chlorphenesin.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Chlorphenesin.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Chlorphenesin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Chlorphenesin.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Chlorphenesin.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Chlorphenesin.Approved
SecoisolariciresinolChlorphenesin may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Chlorphenesin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Chlorphenesin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Chlorphenesin.Investigational
SertralineSertraline may increase the antiplatelet activities of Chlorphenesin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Chlorphenesin.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Chlorphenesin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Chlorphenesin.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Chlorphenesin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Chlorphenesin.Experimental
Synthetic Conjugated Estrogens, AChlorphenesin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BChlorphenesin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Chlorphenesin.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Chlorphenesin.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Chlorphenesin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Chlorphenesin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Chlorphenesin.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Chlorphenesin.Approved
TiboloneChlorphenesin may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Chlorphenesin.Investigational
TioclomarolChlorphenesin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Chlorphenesin.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Chlorphenesin.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Chlorphenesin.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Chlorphenesin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Chlorphenesin.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Chlorphenesin.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Chlorphenesin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Chlorphenesin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Chlorphenesin.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the antiplatelet activities of Chlorphenesin.Approved
WarfarinChlorphenesin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Chlorphenesin.Approved, Investigational
ZeranolChlorphenesin may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Chlorphenesin.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Chlorphenesin.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Chlorphenesin.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Parker, H.E.; U S . Patent 3,214,336; October 26, 1965; assigned to The Upjohn Company. Collins, R.J. and Matthews, R.J.; US. Patent 3,161,567; December 15, 1964; assigned to The Upjohn Company.

General References
  1. Malley A, Baecher L: Inhibition of histamine and SRS-A from monkey lung tissue by chlorophenesin. J Immunol. 1971 Aug;107(2):586-8. [PubMed:4105542]
  2. Kurachi M, Aihara H: Effect of a muscle relaxant, chlorphenesin carbamate, on the spinal neurons of rats. Jpn J Pharmacol. 1984 Sep;36(1):7-13. [PubMed:6503049]
  3. Dalessio DJ: Medical treatment of the major neuralgias. Semin Neurol. 1988 Dec;8(4):286-90. [PubMed:3074423]
External Links
Human Metabolome Database
HMDB0014994
KEGG Compound
C07928
PubChem Compound
7697
PubChem Substance
46504714
ChemSpider
7411
ChEBI
3642
ChEMBL
CHEMBL388751
PharmGKB
PA164784022
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorphenesin
ATC Codes
D01AE07 — Chlorphenesin
MSDS
Download (35.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
Packagers
Not Available
Dosage forms
FormRouteStrength
OintmentTopical
CreamTopical10 mg
CreamTopical1.0 %
PowderTopical10 mg
PowderTopical1 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)86–92Salim, E.F., Booth, R.E. (1967). "Qualitative and quantitative tests for chlorphenesin carbamate". Journal of Pharmaceutical Sciences 56 (5): 623–4. doi:10.1002/jps.2600560516. PMID 6032776.
water solubility1E+004 mg/LMERCK INDEX (1996); less than
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.4 mg/mLALOGPS
logP1.46ALOGPS
logP1.1ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.69 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity49.58 m3·mol-1ChemAxon
Polarizability20.1 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9803
Blood Brain Barrier+0.6433
Caco-2 permeable-0.5562
P-glycoprotein substrateNon-substrate0.5768
P-glycoprotein inhibitor INon-inhibitor0.8531
P-glycoprotein inhibitor IINon-inhibitor0.9212
Renal organic cation transporterNon-inhibitor0.8694
CYP450 2C9 substrateNon-substrate0.8815
CYP450 2D6 substrateNon-substrate0.8373
CYP450 3A4 substrateNon-substrate0.7335
CYP450 1A2 substrateInhibitor0.6099
CYP450 2C9 inhibitorNon-inhibitor0.9114
CYP450 2D6 inhibitorNon-inhibitor0.9292
CYP450 2C19 inhibitorNon-inhibitor0.6201
CYP450 3A4 inhibitorNon-inhibitor0.9412
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8428
Ames testNon AMES toxic0.7102
CarcinogenicityNon-carcinogens0.8053
BiodegradationNot ready biodegradable0.8233
Rat acute toxicity2.1025 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Non-inhibitor0.8296
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Secondary alcohols / 1,2-diols / Primary alcohols / Organochlorides / Hydrocarbon derivatives
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Monocyclic benzene moiety / Aryl halide / Aryl chloride / 1,2-diol / Secondary alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
propane-1,2-diols, monochlorobenzenes, glycol (CHEBI:3642)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Not Available
Gene Name
CYP2B
Uniprot ID
Q14097
Uniprot Name
CYP2B protein
Molecular Weight
43147.81 Da
References
  1. Jarukamjorn K, Sakuma T, Nemoto N: Discriminating activation of CYP2B9 expression in male C57BL/6 mouse liver by beta-estradiol. Biochem Biophys Res Commun. 2000 Dec 9;279(1):288-92. [PubMed:11112454]
  2. Nims RW, Lubet RA, Fox SD, Jones CR, Thomas PE, Reddy AB, Kocarek TA: Comparative pharmacodynamics of CYP2B induction by DDT, DDE, and DDD in male rat liver and cultured rat hepatocytes. J Toxicol Environ Health A. 1998 Mar 27;53(6):455-77. [PubMed:9537282]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Holloway AC, Stys KA, Foster WG: DDE-induced changes in aromatase activity in endometrial stromal cells in culture. Endocrine. 2005 Jun;27(1):45-50. [PubMed:16077170]
  2. Younglai EV, Holloway AC, Lim GE, Foster WG: Synergistic effects between FSH and 1,1-dichloro-2,2-bis(P-chlorophenyl)ethylene (P,P'-DDE) on human granulosa cell aromatase activity. Hum Reprod. 2004 May;19(5):1089-93. Epub 2004 Apr 7. [PubMed:15070871]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Medina-Diaz IM, Arteaga-Illan G, de Leon MB, Cisneros B, Sierra-Santoyo A, Vega L, Gonzalez FJ, Elizondo G: Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p'-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metab Dispos. 2007 Jan;35(1):95-102. Epub 2006 Oct 11. [PubMed:17035600]
  2. Petersen MS, Halling J, Damkier P, Nielsen F, Grandjean P, Weihe P, Brosen K: Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicol Appl Pharmacol. 2007 Oct 15;224(2):202-6. Epub 2007 Jul 14. [PubMed:17692354]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Springer RH, Dimmitt MK, Novinson T, O'Brien DE, Robins RK, Simon LN, Miller JP: Synthesis and enzymic activity of some novel xanthine oxidase inhibitors. 3-Substituted 5,7-dihydroxypyrazolo(1,5-alpha)pyrimidines. J Med Chem. 1976 Feb;19(2):291-6. [PubMed:2778]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Fernandez P, Guillen MI, Gomar F, Aller E, Molina P, Alcaraz MJ: A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis. Biochem Pharmacol. 2004 Aug 1;68(3):417-21. [PubMed:15242808]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Westlake GE, Bunyan PJ, Stanley PI, Walker CH: The effects of 1,1-di(p-chlorophenyl)-2-chloroethylene on plasma enzymes and blood constituents in the Japanese quail. Chem Biol Interact. 1979 May;25(2-3):197-210. [PubMed:466732]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:38